Stockwinners Market Radar for June 23, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:22 EDT Cathie Wood's ARK Investment bought 97.5K shares of TuSimple today

19:17 EDT NerdWallet to acquire On The Barrelhead in roughly $120M deal - NerdWallet announced the entry into an acquisition agreement with On the Barrelhead, Inc., a data-driven platform that provides consumers and SMBs with credit-driven product recommendations to help improve their financial lives. Through this acquisition, On the Barrelhead will fully integrate into NerdWallet's existing teams, brand, products and technology. "Our vision for a trusted financial ecosystem means we're able to provide consumers and SMBs with a trusted platform to learn about various financial topics, shop for products, connect their data and receive data-driven nudges," said Tim Chen, CEO and Co-founder of NerdWallet. "On the Barrelhead's data and technology solutions will help us advance toward our goal by enabling us to leverage consumer information to provide users with relevant financial guidance and more personalized and compelling product recommendations. Their differentiated technology solutions and NerdWallet's trusted brand and reach will also strengthen our footprint in the lending space by providing significant value to our partners." For the twelve months ended December 31, 2021, On the Barrelhead generated approximately $38M in revenue, growing roughly 90% year-over-year, and $5M in net income. NerdWallet believes the acquisition of On the Barrelhead would have been accretive to NerdWallet's revenue and adjusted EBITDA for the year ended December 31, 2021. NerdWallet expects the acquisition will be accretive to NerdWallet's 2022 revenue and adjusted EBITDA and reconfirms previously announced expected year-over-year increase in its 2022 annual adjusted EBITDA margin. Under the terms of the merger agreement, NerdWallet will acquire all of the outstanding shares of On the Barrelhead for total consideration of approximately $120M, subject to customary purchase price adjustments, consisting of approximately $70M in cash and $50M in NerdWallet Class A common stock. The NerdWallet equity issued as part of the transaction will be determined based on the 30-trading day volume-weighted-average price as of June 22, 2022, or $10.37 per share, and half of the equity will have a two-year lock-up restriction. NerdWallet expects to finance the cash portion of the acquisition with borrowings from its existing credit facility. A new compensatory bonus retention pool of approximately $30M has been planned for On the Barrelhead management. The transaction is subject to customary closing conditions and is expected to close in the third quarter of 2022.

18:49 EDT PNC Financial releases results of Dodd-Frank stress tests - PNC Financial Services announced the results of its biennial company-run stress test conducted in accordance with regulations of the Board of Governors of the Federal Reserve System and the Office of the Comptroller of the Currency under the Dodd-Frank Wall Street Reform and Consumer Protection Act. The projection period for the 2022 test covers Jan. 1, 2022 to March 31, 2024. Under the hypothetical severely adverse scenario provided by the agencies, PNC estimates that its ending and minimum regulatory capital ratios would be as follows: Common Equity Tier 1 9.1%, Tier 1 Risk-Based Capital 10.4%, Total Risk-Based Capital 12.8%, and Tier 1 Leverage 7.2%.

18:13 EDT Zendesk jumps 33% to $77 after WSJ report about potential buyout deal

17:50 EDT Primoris awarded $260M solar project - Primoris announced a solar project with an estimated value of $260M. The contract was secured by the company's Energy/Renewables Segment. The award is for the engineering, procurement and construction of a utility-scale solar facility in the South. Initial project construction will begin in 3Q22 with completion of the project expected in 4Q23.

17:23 EDT FedEx sees raising package prices above inflation rate - Sees Q1 volumes continuing to be pressured. Sees lower number of consumer packages as consumers spend on services. Says facility investment in Ground unit will decline.

17:20 EDT Scorpio Tankers announces purchase of shares by President Robert Bugbee - Scorpio Tankers announces that the President of the company, Robert Bugbee, has purchased 50,000 common shares of the company in the open market at an average price of $33.89 per share.

17:15 EDT Beneficial owner of Arcellx New Enterprise Associates buys $5M in shares - Beneficial owner of Arcellx New Enterprise Associates disclosed in a filing that it had purchased 312,500 shares of company stock at $16 per share on June 21, for a total transaction amount of $5,000,000

17:09 EDT Lockheed Martin awarded $581.64M Air Force contract - Lockheed Martin has been awarded an indefinite-delivery/indefinite-quantity contract in the amount of $581.64M for Global Positioning System, or GPS, IIR IIR-M III IIIF On-Orbit Support. This contract will provide engineering services to the operational units in support of GPS Block IIR/IIR-M/III/IIIF satellite constellation. It encompasses, but is not limited to, technical expertise, system administration for government furnished property, cybersecurity, special studies, data collection, and anomaly resolution. The Space Systems Command Directorate of Contracting is the contracting activity.

17:05 EDT FedEx says working through challenges from labor shortage - Says finished FY22 with highest-ever revenue and operating income. Says FY22 results a testament to merits of long-term strategy. Says working through various inefficiencies caused by labor shortages. Says Express unit delivered record quarterly operating income and revenue despite challenges. Says experienced modest revenue growth in Ground unit in Q4. Comments taken from Q4 earnings conference call.

16:59 EDT Bausch Health chairman Joseph Papa resigns, Paulson named new chairman - Bausch Health announced the results of its 2022 annual meeting of shareholders and certain other updates with respect to the company's Board of Directors. The company also announced that Joseph C. Papa resigned from the Board, effective immediately. Papa's decision to resign from the Board was not due to any dispute or disagreement with the company, its management or the Board on any matter relating to the company's operations, policies or practices. The Board appointed John A. Paulson to the Board to fill the resulting vacancy, effective upon Papa's resignation. Paulson will also serve as the Chairperson of the Board. The Board has not determined at this time the committees, if any, to which Paulson will be appointed. Pursuant to the company's Corporate Governance Guidelines, because Paulson is an independent director, the Board will no longer have the position of Lead Independent Director. The current Lead Independent Director, Ross, will continue to serve on the Board.

16:46 EDT Bar Harbor Bankshares announces stock repurchase plan for up to 751K shares - Bar Harbor Bankshares "announced that its Board of Directors authorized the repurchase of up to 5% of its outstanding common stock, representing approximately 751,000 shares as of May 31, 2022 under a share repurchase plan. The Plan is authorized to last no longer than twelve months."

16:40 EDT Campbell Soup VP Slavtcheff sells $616K in company shares - Campbell Soup VP Craig Slavtcheff disclosed in a regulatory filing that he had sold 13,110 shares of company stock at $47 per share on June 23, for a total transaction amount of $616,170.

16:37 EDT Fed releases stress test results, says banks still have strong capital levels - The Federal Reserve Board on Thursday released the results of its annual bank stress test, which showed that banks continue to have strong capital levels, allowing them to continue lending to households and businesses during a severe recession. All banks tested remained above their minimum capital requirements, despite total projected losses of $612B. Under stress, the aggregate common equity capital ratio-which provides a cushion against losses-is projected to decline by 2.7 percentage points to a minimum of 9.7% which is still more than double the minimum requirement. Publicly traded companies in the space include Bank of America (BAC), Citi (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC). Reference Link

16:34 EDT Oragenics appoints Kimberly Murphy as CEO and President - Oragenics appointed Kimberly Murphy, member of the board of directors, as President and CEO effective June 23. Murphy served as leader in the US and Global launch of Merck's HPV/Gardasil Franchise. Murphy joined Oragenics' Board of Directors in 2020. Most recently Murphy served as VP of the Influenza Franchise and Global Vaccine Commercialization Leader at GSK, with responsibility for the global influenza vaccines business and also served as Vice President and Global Marketing Head for GSK's shingles vaccine. Murphy was VP and Lead for the North America Vaccines Integration Planning Team where she integrated GSK's acquisition of Novartis AG's vaccine division and served as Vice President of U.S. Vaccines Customer Strategy and as Senior Director of U.S. Influenza Portfolio Strategy.

16:32 EDT Encore Capital general counsel Greg Call to retire, Andrew Asch to succeed - Encore Capital announced that Andrew Asch will be promoted to the role of senior VP, general counsel effective August 15. Asch has been with the company since 2010 and currently serves as senior VP, general counsel of Encore's subsidiary Midland Credit Management, or MCM. He will report to Encore's president and CEO, Ashish Masih, and serve on Encore's executive leadership team. Asch's appointment to the position will follow the retirement of Greg Call, executive VP, general counsel and chief administrative officer. Call joined Encore in 2010, and has overseen a range of functions including legal, enterprise risk management, internal audit, government relations, human resources and information security. Call informed Encore of his intent to retire and will remain with the company through September 1 to support the transition of his role and responsibilities.

16:31 EDT Skylight Health receives Nasdaq notification over minimum bid price - Skylight Health Group announced that the company received written notification from The Nasdaq Stock Market LLC on June 16, 2022, that the company is not in compliance with the minimum bid price requirement set forth in Nasdaq Rules for continued listing on Nasdaq. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the company's common shares for the 30 consecutive business days from May 4, 2022 to June 15, 2022, the company no longer meets the minimum bid price requirement.

16:15 EDT LSB Industries set to join the Russell 3000 Index - LSB Industries is set to join the broad-market Russell 3000 Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the US market opens on June 27, according to a preliminary list of additions posted June 3. "Our addition to the Russell 3000 is a testament to the successful transformation we've executed with our operations and capital structure, coupled with the strength of our end markets," stated Mark Behrman, President, and Chief Executive Officer of LSB Industries. "Becoming a new component of the Russell indices will broaden our shareholder base and raise our profile with the investment community, which we would expect to be beneficial to all of our shareholders."

16:11 EDT CalAmp: Q2 sequential quarterly revenue growth mid-high single digit percentage - The Company is maintaining its policy of not providing quarterly guidance. Visibility into product shipments still remains uncertain due to the global component supply shortages; however, the Company expects sequential quarterly revenue growth in the second quarter to be in the mid to high single digit percentage points.

16:10 EDT ThredUP to join Russell 3000 Index - ThredUp is set to join the broad-market Russell 3000 Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective as of market open on June 27, according to a preliminary list of additions last posted June 17.

16:09 EDT Smith & Wesson Brands reports Q4 gross margin 39.8% vs. 45.1% last year

16:08 EDT Smith & Wesson Brands CEO expects 'inflationary pressures to persist' - Mark Smith, President and CEO, commented, "Our fourth quarter and full year results speak to the quality and dedication of our employees, the strength of our iconic brand, and the resiliency of our flexible manufacturing model. We delivered strong financial results, including gross profit and Adjusted EBITDAS margins for fiscal 2022 that exceeded prior year levels despite continued moderation in demand for firearms that led to lower net sales. Although we expect inflationary pressures to persist and for firearm market conditions to return to more normalized levels in fiscal 2023, we are confident in our flexible manufacturing model and expect to benefit from the pricing and product portfolio adjustments that we made during the surge. In summary, we believe that we remain well positioned for long-term growth with an agile business model designed to quickly adapt to changes in the marketplace and deliver strong, consistent levels of profitability and drive long-term stockholder value." Deana McPherson, Executive Vice President and CFO, commented "Our financial performance reflects tougher year-over-year comparisons due to the return to more normalized levels of demand following the surge. However, in spite of the lower demand, we are now realizing the benefits of the proactive steps we took during the surge to enhance our profitability profile. Fourth quarter gross margin was down on a year-over-year basis, as expected, but 760 basis points above the comparable quarter in fiscal 2020 despite a 6.1% decline in net sales. Our balance sheet remains strong with $120.7 million of cash and no debt, and we expect to continue generating strong cash flow for the foreseeable future. Accordingly, our Board of Directors has authorized a 25% increase in our quarterly dividend to $0.10 per share, which will be paid to stockholders of record on July 7, 2022 with payment to be made on July 21, 2022."

16:06 EDT Smith & Wesson Brands raises quarterly dividend 25% to 10c per share - Which will be paid to stockholders of record on July 7 with payment to be made on July 21.

16:05 EDT Novavax' COVID-19 vaccine granted emergency use authorization in Taiwan - Novavax announced that the Taiwan Food and Drug Administration has granted emergency use authorization for Nuvaxovid COVID-19 vaccine in individuals aged 18 years and over. Novavax and Taiwan have executed a supply agreement and the doses for Taiwan would represent the first shipment of Nuvaxovid to a country participating under the COVAX Facility. The EUA was based on the totality of preclinical, manufacturing and clinical trial data submitted for review. Novavax will continue to collect and analyze real-world data, including the monitoring of safety and the evaluation of variants, as the vaccine is distributed. The Coalition for Epidemic Preparedness Innovations has provided critical support to Novavax, including the commitment of approximately $400M to advance early clinical development and manufacturing scale-up around the globe. Nuvaxovid has received authorization for use in individuals aged 18 and over from more than 40 countries in addition to Emergency Use Listing from the World Health Organization.

16:02 EDT Anebulo Pharmaceuticals to announce topline data for ANEB-001 on July 5th - Anebulo Pharmaceuticals "anticipates releasing topline data from Part A of its ongoing Phase 2 study of ANEB-001 on July 5th. The results of the study, conducted in sixty healthy subjects challenged with delta-9-tetrahydrocannabinol, better known as THC, will be used to design the next step forward in the clinical trial for ANEB-001 as a potential treatment of ACI." Simon Allen, CEO, said: "The data will allow us to prepare for the exciting next phase of development of our potent, small molecule CB1 antagonist as a novel and to our knowledge, the most advanced antidote for ACI in clinical development, an indication for which there is no FDA approved treatment. On behalf of the Anebulo Team, we look forward to presenting the data after the Independence Day Holiday."

15:40 EDT Genenta Science SpA(ADR) trading halted, volatility trading pause

14:41 EDT Novavax says Nuvaxovid recommended for expanded conditional authorization in EU - Novavax announced that the Nuvaxovid COVID-19 vaccine has been recommended for expanded conditional marketing authorization in the European Union for adolescents aged 12 through 17. The Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency based its opinion on results from the Phase 3 PREVENT-19 clinical trial. "This recommendation brings us closer to offering adolescents in the EU the first protein-based COVID-19 vaccine developed using an innovative approach to traditional technology," said Stanley Erck, President and CEO of Novavax. The European Commission granted CMA for Nuvaxovid to prevent COVID-19 in people 18 years of age and over in December 2021. In the 12 through 17 year-old population, emergency use authorization has been granted in India, the company noted.

13:58 EDT Keurig Dr Pepper to acquire Atypique brand, terms not disclosed - Keurig Dr Pepper announced a definitive agreement to acquire the global rights to the non-alcoholic, ready-to-drink cocktail brand Atypique from Station Agro-Biotech, a Quebec-based company that specializes in the manufacturing and marketing of alcoholic and non-alcoholic beverages. Terms of the deal, which is expected to close in early Q4, were not disclosed. The agreement includes a multi-year collaboration between the two companies to fuel accelerated growth for Atypique, leveraging Station Agro-Biotech's R&D expertise in the category and KDP's robust sales and distribution network. "At Keurig Dr Pepper, we strongly believe in innovation to drive growth to meet the evolving beverage needs of consumers," said Ozan Dokmecioglu, CFO & President of International. "We are excited to add this new platform to our powerful portfolio in Canada, and the global rights to Atypique provides optionality to further expand the brand's growth potential." Olivier Lemire, President of Keurig Dr Pepper Canada, added, "Atypique is a great complement to our successful ready-to-drink alcohol portfolio, and we look forward to continue innovating around this brand to drive accelerated growth."

13:32 EDT KFC appoints Tarun Lal as president, KFC U.S. - Kentucky Fried Chicken announced that Tarun Lal has been named President of KFC U.S., effective July 15, 2022. Lal is currently managing director of the KFC Middle East, Pakistan, Turkey, Africa and India markets and is a 25-year KFC brand veteran. He will report to Dyke Shipp, KFC Division President, and relocate to the KFC U.S. headquarters in Louisville, Ky. Lal replaces Kevin Hochman, who departed KFC U.S. on June 3 to assume a senior position at another public company.

13:00 EDT Conn's HomePlus announces new store in Santa Fe, New Mexico - Conn's HomePlus is expanding in New Mexico with the opening of a new 40,000 square foot retail location in the Santa Fe Place Mall at 4350 Cerillos Road in Santa Fe. A grand opening celebration is scheduled for Saturday, June 25, 2022, featuring food trucks and special promotions, including coupons and free prizes for guests. "We're excited to grow our presence in New Mexico and introduce our wide selection of home products to customers in the Santa Fe area who are looking to turn their home life to home love," said Chandra Holt, President and CEO of Conn's HomePlus. "We believe customers here will appreciate our next-day delivery service, and their ability to choose the payment option that works best for them."

12:29 EDT Eni SpA postpones IPO of Plenitude due to market conditions - Eni S.p.A announced it will postpone the Initial Public Offering of ordinary shares in Eni Plenitude S.p.A. Societa Benefit, or "Plenitude," for the listing on Euronext Milan, a regulated market which is organized and managed by Borsa Italiana S.p.A.. "Market conditions have deteriorated since Eni and Plenitude announced the Intention to Float on 9 June. While there was strong and widespread investor interest in Plenitude and important support for its strategy, Eni has concluded that the volatility and uncertainty currently affecting the markets require a further phase of monitoring. Eni and Plenitude will continue to monitor market conditions and deliver their strategy of offering decarbonized energy to their customers, through the development of renewables and electric mobility investments," the company stated. Reference Link

12:17 EDT Staffing 360 Solutions announces 1-for-10 reverse stock split - Staffing 360 Solutions announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares. The reverse stock split will become effective at 4:05 p.m. on Thursday, June 23, 2022. Staffing 360's common stock will continue to be traded on the Nasdaq Capital Market under the symbol STAF and will begin trading on a split-adjusted basis when the market opens on Friday, June 24, 2022. At a special meeting of stockholders held on June 23, 2022, Staffing 360's stockholders granted the Company's Board of Directors the discretion to effect a reverse stock split of Staffing 360's common stock through an amendment to its Amended and Restated Certificate of Incorporation at a ratio of not less than 1-for-2 and not more than 1-for-20, such ratio to be determined by the Company's Board of Directors. At the effective time of the reverse stock split, every ten shares of Staffing 360's issued and outstanding common stock will be converted automatically into one issued and outstanding share of common stock without any change in the par value per share. Stockholders holding shares through a brokerage account will have their shares automatically adjusted to reflect the 1-for-10 reverse stock split. It is not necessary for stockholders holding shares of the Company's common stock in certificated form to exchange their existing stock certificates for new stock certificates of the Company in connection with the reverse stock split, although stockholders may do so if they wish.

12:12 EDT Rackspace announces selection by VMware as strategic SASE deployment partner - Rackspace Technology (RXT) announced VMware (VMW) has selected Rackspace Technology as a strategic deployment partner for its Secure Access Service Edge, or SASE, platform. VMware SASE will be initially deployed in 15 of the Rackspace Technology global partner data centers with another five data centers planned for additional phases, the company reported. "We are thrilled that VMware has selected Rackspace Technology to roll out the next phase of its SASE platform. SASE is defining a new era in cloud network security. Our already long-standing partnership with VMware just emphasizes the expertise we are able to deliver simultaneously to help companies securely leverage the benefits of the cloud, including Edge," said PV SubbaRao, Vice President of Enterprise at Rackspace Technology.

12:09 EDT Teledyne FLIR awarded $48M nano-UAV framework agreement - Teledyne FLIR Defense announced that it has entered into a framework agreement worth up to NOK 475M, approximately $48M, with the Norwegian Defence Materiel Agency to deliver advanced Black Hornet nano unmanned aerial vehicles. The agreement is valid for four years but can be extended a year at a time for up to three additional years.

12:05 EDT Spotify introduces new Live Events Feed, replacing Concert Hub - Spotify said it is introducing a new Live Events Feed, replacing the Concert Hub, and introducing a number of updates to help fans find their favorite creators' live events. Users can find the new feed by searching "Live Events" in the app. "The Live Events Feed is our new in-app destination where you can discover all the live events in your local area, personalized to you," the company said. "We've sourced these listings from our ticketing partners-Ticketmaster, AXS, DICE, Eventbrite, See Tickets, and more. Plus, alongside this revamped feed, we're launching new places within the app to help you stay in the know about upcoming events in your area from the artists you love. All in all, the Live Events Feed will help make you even more aware of events you might be interested in, and help you to make more confident decisions when purchasing tickets-all by putting the right event in the hands of the right fan at the right moment."

12:02 EDT FTC orders Harley-Davidson to abide by right-to-repair rules - The Federal Trade Commission is taking action against motorcycle manufacturer Harley-Davidson Motor Company Group, LLC and Westinghouse outdoor generator maker MWE Investments, LLC for illegally restricting customers' right to repair their purchased products. The FTC's complaints charge that the companies' warranties included terms that conveyed that the warranty is void if customers use independent dealers for parts or repairs. The FTC is ordering Harley-Davidson and Westinghouse to fix warranties by removing illegal terms and recognizing the right to repair, come clean with customers, and ensure that dealers compete fairly with independent third-parties. "Consumers deserve choices when it comes to repairing their products, and independent dealers deserve a chance to compete," said Samuel Levine, Director of the FTC's Bureau of Consumer Protection. "These orders require Harley and Westinghouse to fix their warranties, come clean with consumers, and ensure fair competition with independent providers. Other companies that squelch consumers' right to repair should take notice."

12:00 EDT Deutsche Bank falls -11.8% - Deutsche Bank is down -11.8%, or -$1.21 to $9.01.

12:00 EDT Eqonex's Digivault appoints Greg Vosper as Chief Commercial Officer - Digivault, the custody business that forms part of EQONEX Limited, a digital assets financial services company, announced the appointment of Greg Vosper as Chief Commercial Officer. "Vosper will sit on the Digivault Leadership Team. As Chief Commercial Officer, Vosper will be responsible for driving business development, partnerships and sales strategy for Digivault. Working closely with CEO Robert Cooper, Vosper's objectives are to accelerate the business's growth and commercial opportunities," the company stated.

12:00 EDT UserTesting rises 14.7% - UserTesting is up 14.7%, or 68c to $5.32.

12:00 EDT Azure Power rises 24.0% - Azure Power is up 24.0%, or $2.56 to $13.20.

11:32 EDT Wynn Resorts Macau announces concession extension agreement - Wynn Resorts Macau S.A. announces that it has entered into the Concession Extension Agreement with the Macau SAR Government, to extend the gaming concession of Wynn from June 26, 2022 to December 31, 2022. "Wynn would like to express its sincere gratitude to the Government for its guidance during the Concession Extension Agreement process. Wynn believes that this extension will enable it to make continued contributions to the future development of Macau and the local community. We look forward to the announcement of the requirements and details of the public tender process for the new gaming concessions and will liaise closely with the government to make thorough preparations for active participation in the bidding. The approval of the Gaming Law Amendment Act has laid an essential long-term foundation to facilitate the orderly, healthy, and sustainable development of the industry. In addition to adhering to the relevant requirements of the Act, Wynn will continue to fulfil its social responsibilities and fully support the Government in promoting the moderate diversification of Macau's economic development, enhancing its competitiveness in integrated leisure and tourism, and further strengthening its profile among international tourists. Wynn will also actively cooperate with the Government to enrich the development of Macau as a world center of tourism and leisure. In accordance with the terms of the Concession Extension Contract, Wynn has paid to the Macau SAR Government MOP47 million, equivalent to approximately HKD45.6 million, upon signing of the Concession Extension Agreement as contract premium for the extension," Wynn stated.

11:07 EDT Golden Sun Education Group Ltd trading resumes

11:02 EDT Golden Sun Education Group Ltd trading halted, volatility trading pause

10:46 EDT Noble Corp trading resumes

10:33 EDT Noble Corp. to sell five jackup rigs for $375M - Noble Corporation announced that it has entered into an asset purchase agreement to sell five jackup rigs for $375 million to a newly formed subsidiary of Shelf Drilling, whose obligations under the asset purchase agreement will be guaranteed by Shelf Drilling. The sale, which is subject to approval of the UK Competition and Markets Authority, is intended to address the potential concerns identified by the CMA in the Phase I review of the proposed business combination between Noble and The Drilling Company of 1972 A/S announced on 10 November 2021. The Remedy Rig Sale Agreement includes the rigs Noble Hans Deul, Noble Sam Hartley, Noble Sam Turner, Noble Houston Colbert, and Noble Lloyd Noble and all related support and infrastructure. Associated offshore and onshore staff are expected to transfer with the Remedy Rigs. Following the sale, Noble expects to continue to perform the current drilling program for the Noble Lloyd Noble under a bareboat charter arrangement with Shelf Drilling until the second quarter of 2023 when the primary term of its current drilling contract is expected to end. The charter arrangement would pass the economic benefit of the drilling contract to Shelf Drilling. Drilling contracts for other Remedy Rigs are expected to be novated to the Buyer, subject to the clients' consent. Noble will provide certain customary transition support services to the Buyer for a limited period of time. The Buyer is expected to finance the acquisition through equity and debt financings by the Buyer and Shelf Drilling, but the purchase is not conditioned on such financing. The Remedy Rig Sale is expected to close promptly following closing of the Business Combination. Additional information related to our Remedy Rig Sale will be provided in an 8-K expected to be filed by the Company on June 23, 2022. On 9 May 2022 the CMA published its decision that there are reasonable grounds for believing that a sale to a suitable purchaser of the Remedy Rigs together with sufficient supporting infrastructure might be accepted by the CMA to address its concerns related to lessening of competition created by the Business Combination. The duration and outcome of the CMA review process remains uncertain. If the Buyer, Remedy Rig Sale Agreement and the Remedy Proposal are accepted by the CMA, closing of the Business Combination is expected to occur near the end of the third quarter of 2022. In connection with the Business Combination, Noble currently expects to launch the planned exchange offer for shares of Maersk Drilling in August 2022. In addition to the CMA approval, completion of the Business Combination remains subject to acceptance by holders of at least 80% of Maersk Drilling shares, listing of Noble shares on the NYSE and Nasdaq Copenhagen, and other customary conditions.

10:29 EDT FDA denies authorization to market JUUL products

10:22 EDT Liquid Media partners with Vuulr for entertainment solutions - Liquid Media Grou announced the signing of a strategic partnership with Vuulr. The landmark agreement with is the first to leverage the Company's full-service offering, which integrates Liquid's portfolio companies and partners through their network of services. Marketplace services provided to Vuulr by Liquid are scheduled to include content evaluation in partnership with Liquid's data and analytics, including its partnership with Slated, fulfillment servicing with Digital Cinema United, festival promotions via iGems and Liquid's Filmocracy partnership. Liquid will also be listing hundreds of titles from independent content creators from its Projektor and Slipstream catalog on Vuulr, supported by Liquid's theatrical and content licensing sales team. The partnership agreement calls for Liquid to offer alternative funding opportunities to Vuulr's sellers and buyers through integration into the content financing marketplace so that Vuulr projects can be financed via traditional and Web3 crowdfunding.

10:21 EDT Noble Corp trading halted, news pending

10:10 EDT EMA recommends extending authorization of Nuvaxovid for ages 12 to 17 - The EMA's human medicines committee, or CHMP, has recommended granting an extension of indication for the COVID-19 vaccine Nuvaxovid to include use in adolescents aged 12 to 17 years, the European Medicines Agency announced. The vaccine, developed by Novavax, is already approved for use in adults aged 18 and above. The use of the vaccine in adolescents is the same as in adults, with two injections given in a muscle, three weeks apart. Reference Link

10:00 EDT Deutsche Bank falls -9.2% - Deutsche Bank is down -9.2%, or -94c to $9.28.

10:00 EDT Grove falls -17.2% - Grove is down -17.2%, or -$1.32 to $6.35.

10:00 EDT Terran Orbital rises 12.1% - Terran Orbital is up 12.1%, or 64c to $5.96.

09:56 EDT Connexa Sports partners with Prairie Trail Sports Complex - Connexa Sports announced that its wholly owned subsidiary, PlaySight Interactive is partnering with Prairie Trail Sports Complex, set to open Fall 2022 in Ankeny, Iowa. Prairie Trail SC is the newest multisport complex to bring PlaySight's live streaming and performance video platform to its facilities, including four basketball courts and four volleyball courts.

09:51 EDT Phoenix Motor Inc trading resumes

09:47 EDT Boise Cascade falls -5.7% - Boise Cascade is down -5.7%, or -$3.58 to $58.83.

09:47 EDT SIGNA Sports United rises 14.6% - SIGNA Sports United is up 14.6%, or 89c to $7.00.

09:47 EDT Heliogen rises 16.9% - Heliogen is up 16.9%, or 53c to $3.67.

09:46 EDT Avaya Holdings trading halted, news pending

09:44 EDT Cinedigm plans to triple podcast lineup by end of fiscal year next March - Cinedigm announced that the Cinedigm Podcast Network has reached 50 million downloads and plans to triple its podcast lineup to 75 titles by the end of its fiscal year next March. To date, the Company owns or distributes 25 podcasts through its Bloody Disgusting and Fandor brands, up 127% from 11 as of March of this year. Future podcast endeavors will fall under the above banners, with Cinedigm also actively pursuing opportunities to create audio content associated with its other brands dedicated to serving enthusiast fans across other genres.

09:34 EDT SciSparc announces Ethics Committee approval to conduct trial in ASD - SciSparc announced that it has received approval from the Ethics Committee of The Soroka University Medical Center, in Be'er-Sheva, Israel, to conduct the Company's clinical trial for SCI-210 in patients suffering from Autism Spectrum Disorder. The trial will investigate the effect of the Company's drug candidate SCI-210, a proprietary combination of cannabidiol and CannAmide, versus CBD monotherapy, in treating ASD. The trial's objectives are to evaluate the safety, tolerability and efficacy of SCI-210 in children with ASD in a designed 20-week, randomized, double-blind, placebo controlled with a cross-over clinical trial of 60 children. The trial has three primary efficacy end points: the Aberrant Behavior Checklist-Community parent questionnaire; the Clinical Global Impressions-Improvement performed by a clinician; and the effective therapeutic dose. The launch of the trial is pending further approvals by the Israeli Ministry of Health and the Israeli Medical Cannabis Agency.

09:27 EDT Alliant Energy adjusts timing of Wisconsin-based generation retirement dates - Alliant Energy is transitioning its energy mix to cleaner, more renewable energy to benefit customers. This includes breaking ground on six new solar projects. In total, the company is moving forward on 12 solar projects that will bring nearly 1,100 megawatts of solar generation online in Wisconsin. It's all part of Alliant Energy's continued drive to diversify its energy mix of generation resources to meet the ongoing energy needs of customers. The uncertainty de Leon mentions includes global supply chain and economic challenges along with shifting Midcontinent Independent System Operator requirements beyond 2022 and regional short-term reliability concerns. Earlier this month, MISO released a study forecasting the MISO region, which includes Manitoba, Canada and parts of 15 states including Wisconsin, could be facing a potential energy shortage for the summer of 2023. Alliant Energy expects to be out of coal generation in Wisconsin by mid-2026. The company also confirms they are still on track to achieve their 2030 goal of reducing fossil fuel generation carbon dioxide emissions by 50%. Alliant Energy now intends to retire Edgewater Generating Station in Sheboygan by June 2025; both remaining Columbia Energy Center units in Portage will be retired by June 2026. The short-term extension demonstrates the company's ongoing commitment to providing reliable energy for all customers as outlined in their Clean Energy Blueprint. Final timing and retirement dates are subject to additional state and regional regulatory reviews.

09:26 EDT Crackle launches updated app on Roku devices - Crackle Plus (CSSE) announced an updated Crackle app on Roku (ROKU) devices. The streaming service has made drastic improvements to their Roku application, now providing a superior user experience as its audience views thousands of hours of free ad-supported content, including award-winning Crackle originals and exclusive programming. 85% of Crackle's total audience now experiences the new, improved user interface. The improvements to the Crackle app environment on Roku devices include an all-new design throughout the application that will provide a more intuitive browsing experience for the audience. Some enhancements include a new navigation menu that makes it easier for viewers to find their favorite TV shows and movies available for free on Crackle. For those viewers who aren't sure what to watch, the Crackle team has improved both the search capabilities and the catalog browsing experience to better combat scrolling fatigue. Once a title has been chosen, users will watch their selection with an updated video player and easy-to-use controls.

09:23 EDT GE Healthcare introduces wireless patient monitoring solution - With most hospitals around the world currently relying on manual "spot-checks" to monitor patient vitals, GE Healthcare has unveiled Portrait Mobile, a wireless patient monitoring system that enables continuous monitoring throughout a patient's stay. The system helps clinicians detect patient deterioration. Early detection of patient deterioration may help reduce length of stay and intensive care unit admissions - and improve patient outcomes. Portrait Mobile includes patient-worn wireless sensors which communicate with a mobile monitor. With Portrait Mobile, respiration rate, oxygen saturation and pulse rate for general ward and post-surgery patients can be captured wirelessly, continuously. This innovation allows caregivers to identify changes that may signal that cardiorespiratory complications or infectious disease may be developing. It gives clinicians the opportunity to act early and potentially avert serious adverse events. For patients, Portrait Mobile's wireless continuous monitoring helps with the ability to move about the hospital, without being restricted to the bedside. This also allows visitors to interact with the patient without technology getting in the way. Moreover, the solution provides patients and family members peace of mind knowing that monitoring is constant - even when the patient is out of their room.

09:21 EDT Global Tech Industries requests review of market making activity - Global Tech Industries Group announced that that it has written to market makers requesting that they review their market making activity in GTII's shares. The company said, "In particular, we informed them of our concerns with the general market making activity in GTII's shares, as it appears that certain market makers have failed to post regular or continuous proprietary quotations that are at or near the market on both sides and that are communicated and represented in a way that makes them widely accessible to investors and other broker-dealers. When market makers fail to meet this requirement, as well as other applicable requirements, it can bring into question whether they are engaging in "bona fide market making" and can avail themselves to any "locate" exemptions afforded to bona fide market makers when executing short sales. The Company is hopeful that each market maker will promptly comply with the request to ensure an orderly market in GTII's shares."

09:19 EDT Radius to be acquired by Gurnet Point, Patient Square for $10 per share plus CVR - Radius Health announced that it has entered into a definitive agreement to be acquired by Gurnet Point Capital and Patient Square Capital in a transaction valued at approximately $890 million, including the assumption of debt and assuming full payment of the CVR. Debt financing for this transaction will be provided by OrbiMed Advisors, LLC. Under the terms of the merger agreement, an entity jointly owned by Gurnet Point and Patient Square will initiate a tender offer to acquire all of the outstanding shares of Radius for $10.00 per share in cash plus a CVR of $1.00 per share payable upon TYMLOS net sales reaching $300 million during any consecutive 12-month period prior to December 31, 2025. Including the CVR payment, Radius shareholders will receive up to an aggregate of $547 million in cash. The upfront payment at closing represents a premium of 45% over the 30-day volume-weighted average price of Radius's common stock, and inclusive of the CVR payment, a 59% premium. Under the terms of the merger agreement, an entity jointly owned by Gurnet Point and Patient Square will promptly commence a tender offer for all outstanding shares of Radius common stock at a price of $10.00 per share in cash plus a CVR of $1.00 per share that is payable upon TYMLOS net sales reaching $300 million during any consecutive 12-month period prior to December 31, 2025. Radius' Board of directors unanimously recommends that Radius shareholders tender their shares in the tender offer. Upon the successful completion of the tender offer, the acquisition subsidiary will be merged into Radius, and any remaining shares of common stock of Radius that were not tendered in the tender offer will be canceled and converted into the right to receive the same consideration payable in the tender offer. The transaction, which has been unanimously approved by the members of the Radius Board, is expected to close in the third quarter of 2022, subject to customary closing conditions, including Radius shareholders tendering a minimum number of shares and receipt of regulatory approvals. The transaction is not subject to a financing condition. Following completion, Radius will become a private company and will no longer be subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, nor be traded on Nasdaq Global Market. The Company plans to maintain operations in the Boston, MA and Wayne, PA areas.

09:09 EDT Cvent to be added to Russell 2000 Index - Cvent announced it has been selected to be added to the Russell 2000 Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the U.S. market opens on June 27.

09:08 EDT Avantor collaborating with GeminiBio for hydrated solutions, cell culture media - Avantor has entered into an agreement with GeminiBio to deliver custom hydrated solutions and cell culture media to the biopharma industry. Custom hydrated solutions and cell culture media are critical components of the bioproduction workflow, especially for emerging modalities such as gene therapy. This collaboration aims to enable customers to utilize custom cGMP products through the full development lifecycle - including early-stage research, scale-up and commercialization.

09:06 EDT GBS to initiate manufacturing on the University of Newcastle Australia campus - GBS announced that the Company and the University of Newcastle in Australia have selected a site for its proprietary biosensor technology. "Maintaining momentum with our partners at the University of Newcastle has been and will remain a principal objective to generating shareholder value and long-term success of the GBS technology," stated Dr. Steven Boyages, Interim Chief Executive Officer. "Our longstanding relationship with the University has matured over the years but as the birthplace of the biosensor technology, the ancestry creates a naturally affinity which has been very productive and efficient for advancing our products forward." After receiving the first delivery of key equipment, the Company has identified an initial site to begin operations on campus. Management along with university leadership and staff will commence this next phase of the commercial buildout that will utilize the already delivered equipment, while the architectural design phase is finalized later this year and the primary manufacturing and construction begins on this second site location. The Company now anticipates construction to commence before end of calendar year 2022.

09:05 EDT Verizon announces new home, business internet options in Manchester - Verizon is turning on its brand new wireless home and business internet services, powered by 5G Ultra Wideband, in parts of Manchester. Verizon Home Internet starts at just $25 per month with AutoPay and a premium 5G mobile plan - all without extra fees, equipment charges, annual contracts or data caps. "Verizon sets the standard when it comes to delivering fast and reliable phone service, so we are excited to bring that same standard of excellence to customers with our Home and Business Internet services to Manchester at a fantastic value," said Chris Flood, Verizon's consumer vice president of the northeast region. "At a time when Americans are looking more closely at their finances, it's important to know that Manchester residents and businesses have a new choice for their wireless internet. You don't need to stay with a pricier provider and you don't have to sacrifice quality to save."

09:04 EDT Seanergy Marine acquires modern capesize vessel from Japanese company - Seanergy Maritime announced that it has agreed to acquire a modern Capesize vessel from a major Japanese company. The Vessel is intended to substitute the Company's oldest vessel, the M/V Gloriuship, which will be spun-off under United Maritime Corporation and will benefit Seanergy's average fleet age and overall operating margin. The Vessel, which will be renamed M/V Honorship, was built in 2010 at a reputable shipyard in Japan and has a cargo-carrying capacity of approximately 180,000 deadweight tons. It is expected to be delivered promptly, within June 2022, subject to the satisfaction of certain customary closing conditions. Moreover, M/V Honorship has been fixed at an index-linked rate at a significant premium over the Baltic Capesize Index for a period employment of about 20 to 24 months with NYK Lines, an existing charterer of the Company. Under the terms of the time charter, the Company has the option to convert the daily hire from index-linked to fixed for a minimum period of two months to a maximum of 12 months based on the same premium over the prevailing Capesize Freight Futures Agreements curve. Stamatis Tsantanis, the Company's Chairman & Chief Executive Officer, stated: "I am pleased to announce the acquisition of another quality Japanese Capesize vessel, which will effectively replace the spin-off of the much older M/V Gloriuship. The planning of the recent sale and purchase transactions has been well-timed in light of improved market conditions compared to the first quarter of the year and the expectation that capesize rates will further improve in the second half of 2022."

09:02 EDT Alpha Pro Tech announces $2M expansion of share repurchase program - Alpha Pro Tech announced that its Board of Directors has authorized a $2M expansion of the Company's existing share repurchase program. With this authorized expansion, the Company now has approximately $2.4M available to repurchase shares of the Company's common stock, $0.4M of which remains from the previous expansion, most recently announced in December 2021. Management anticipates repurchasing shares through open market purchases or through privately-negotiated transactions and intends to retire all shares purchased through the share repurchase program. Open market purchases may be executed by the Company's broker through a pre-arranged repurchase plan, which operates in accordance with the guidelines specified under Rule 10b5-1 and Rule 10b-18 of the Securities Exchange Act of 1934, as amended.

09:02 EDT Senmiao Technology launches ride-hailing platform in Guiyang - Senmiao Technology launched its proprietary online ride-hailing platform for drivers in Guiyang, the capital of Guizhou Province, with a population of approximately 6.1 million. A total of over 2300 rides have been completed in Guiyang on Senmiao's online ride-hailing platform since it was launched on June 14. With the addition of Guiyang, Senmiao's platform is now available in 20 cities across China, including six cities in Sichuan Province and 14 major cities in other provinces in China.

09:01 EDT Fresh Vine continues growth of retail outlet strategy - Fresh Vine Wine announced that its Fresh Vine Wine Rose varietal is available for sale on display at over 100 The Fresh Market grocery stores across Florida, North Carolina, South Carolina, Tennessee, Virginia, Ohio, Illinois, and Massachusetts. Additional markets will be added in July 2022, including Alabama, Arkansas, Georgia, and Oklahoma. With the addition of The Fresh Market, Fresh Vine Wine has added 2,145 new Points of Distribution in the last 90 days for its premium wines, retailing from $14.99 - $22.99.

08:57 EDT Travelzoo board authorizes share repurchase program up to 1M shares - Travelzoo announced that its board of directors has authorized the repurchase of up to 1,000,000 shares of the Company's outstanding common stock.

08:50 EDT Altamira Therapeutics reaches target enrollment in COVAMID trial - Altamira Therapeutics announced that it has reached its targeted enrollment of 136 confirmed subjects in its COVAMID clinical investigation to evaluate the safety, tolerability, and efficacy of its Bentrio nasal spray in patients with acute COVID-19.

08:47 EDT Keurig Dr Pepper recommends stockholders reject TRC Capital mini-tender offer - Keurig Dr Pepper has been notified of an unsolicited "mini-tender" offer by TRC Capital to purchase up to 4M shares of Keurig Dr Pepper's common stock at an offer price of $32.85 net per share in cash, which is an approximate 4.37% discount to the $34.35 per share closing price of Keurig Dr Pepper's common stock on Nasdaq on June 17, and an approximate 5.82% discount to the $34.88 per share closing price of Keurig Dr Pepper's common stock on June 22. Keurig Dr Pepper does not endorse TRC Capital's mini-tender offer and is not associated in any way with TRC Capital, its mini-tender offer or its mini-tender offer documents. Keurig Dr Pepper recommends that its stockholders reject the offer and not tender their shares in response to TRC Capital's below-market offer. TRC Capital has made similar mini-tender offers for the shares of other companies.

08:46 EDT Albireo Pharma announces presentations of new data in liver diseases - Albireo Pharma announced the presentation of new data in pediatric and adult liver diseases at the European Association for the Study of the Liver, EASL, International Liver Congress 2022 being held in London. Bylvay PEDFIC 1 and PEDFIC 2 Data: The Company presented data on Bylvay in five posters. The PEDFIC 1 trial was the first and largest, global, pivotal Phase 3 study conducted in PFIC, which evaluated the efficacy and tolerability of Bylvay in reducing pruritus and serum bile acids in a randomized, double-blind, placebo-controlled trial, and PEDFIC 2 is a long-term, open-label Phase 3 extension study. Key findings from the data include: Bylvay Responders Experience Improvements in Quality of Life Measures. This analysis of pooled data from the PEDFIC studies reveals that all patients had large quality of life deficits at baseline across emotional functioning, social functioning, physical functioning and school functioning, with mean scores between 47 and 67 on the PedsQL. Bylvay Provides Durable Treatment Benefits. In this pooled analysis of data from the PEDFIC studies, Bylvay provided durable clinical treatment benefits in patients with PFIC who received treatment for at least 72 weeks, with mean improvements over time in sBA levels, pruritus, hepatic parameters and growth. Improvements in Pruritus on Bylvay Lead to Improvements in Quality of Life, Hepatic Biomarkers, and Sleep. Results of pooled analysis population of 82 patients treated with Bylvay including 44 pruritus responders of PEDFIC 1 and PEDFIC 2 show that patients across various types of PFIC who had a pruritus response with Bylvay experienced improvements in quality of life, sleep and hepatic biomarkers that were sustained for up to 72 weeks. Bylvay Treatment Impacts Hepatic Parameters, Growth, Sleep, and Biochemical Markers Across PFIC Types. Patients with across various types of PFIC treated with Bylvay for up to 72 weeks, with some tracked up to 128 weeks, experienced reductions in autotaxin levels and increases in C4 levels, as well as variable changes in hepatic parameters, sleep characteristics and growth.

08:46 EDT Kroger raises quarterly dividend 24% to 26c per share - The Kroger Co's Board of Directors approved a dividend increase from 84c to $1.04 per year. The next quarterly dividend of 26c per share will be paid on September 1 to shareholders of record as of close of business on August 15.

08:45 EDT Gaucho Group receives Electrical Masterplan approval by Edemsa - Gaucho Group Holdings announced that its luxury vineyard development project, Algodon Wine Estates, has received Electrical Masterplan approval by Edemsa. Algodon Wine Estates is a 4,138 acre wine, wellness, culinary and sport resort and luxury residential development, in San Rafael, Mendoza, Argentina.

08:42 EDT Eos Energy remains on pace to triple production capacity by year-end - Eos Energy Enterprises announced it remains on pace to triple production capacity to 800 MWh by the end of the year, has recently achieved several significant manufacturing milestones, and installation has begun on the largest energy storage project the Company has delivered to date. In April, Eos shipped its 100th Energy Block energy storage system followed by completing production of the 20,000th battery module in early June at the Company's Turtle Creek, Pennsylvania manufacturing facility. These milestones were accomplished in large part due to incremental production yield increases for three consecutive quarters culminating with crossing the 90% throughput yield threshold in early May. This month, installation began on a 72 MWh Eos Znyth zinc-powered energy storage system at a 102 MW solar + storage facility in South Carolina. The site will house Eos' largest system delivered to date and provide clean power to residents and businesses in the region. These milestones follow substantial progress on the organization's manufacturing facility expansion, which has increased square footage from 60,000 to almost 110,000. The capacity expansion will allow Eos to fill its $212 million orders in backlog as demand for long duration energy storage increases among utilities, commercial and industrial customers throughout the U.S. and abroad. The Company will have created 200 clean energy jobs by year end for the Mon Valley area of Pennsylvania, a region that has traditionally been dedicated to steel production. In a study commissioned by the Company, the Pennsylvania Economy League of Greater Pittsburgh determined that Eos' Turtle Creek facility generates $84 million in economic output and contributes $36 million in value add to the Gross Regional Product of Southwestern Pennsylvania.

08:40 EDT First Solar signs agreement with National Grid for 2 GW of solar modules - First Solar (FSLR) signed a framework agreement with National Grid Renewables (NGG) for 2 gigawatts, gW, DC of advanced, responsibly-produced thin film photovoltaic, PV, solar modules. Scheduled for delivery in 2024 and 2025 throughout the United States, the contracted modules are part of First Solar's advanced Cadmium Telluride thin film module technology platform. The deal was booked prior to the release of First Solar's Q1 2022 earnings in April. Over the past decade, National Grid Renewables and First Solar have partnered on multiple projects, including the recently operational 200-megawatt Prairie Wolf Solar Project in Illinois and the currently under construction Noble Solar and Storage Project in Texas. First Solar's responsibly produced advanced thin film PV modules set industry benchmarks for quality, durability, reliability, design, and environmental performance. First Solar's modules have a carbon footprint that is 2.5 times lower and a water footprint that is three times lower than the average crystalline silicon solar panel made with cells produced in China. "As America's solar company, we're proud of the fact that National Grid Renewables has, once again, selected our technology to power its mission to repower rural American communities," said Georges Antoun, chief commercial officer, First Solar. "Experienced project developers and owner-operators like National Grid Renewables understand the criticality of both, insulating themselves from pricing and supply volatility, and staying true to their values and principles. Both factors are invaluable in helping them successfully navigate some of the industry's headwinds." In addition to its Ohio manufacturing facilities, First Solar also operates factories in Vietnam and Malaysia, and is building a new 3.3 GW factory in India that is expected to be commissioned in the second half of 2023. With First Solar's expansion in the United States and India and optimization of its existing fleet, the company anticipates that its nameplate manufacturing capacity will double to 16 GW in 2024.

08:39 EDT Alliance Entertainment to become public through Adara Acquisition combination - Adara Acquisition (ADRA) announced the signing of a definitive business combination agreement with Alliance Entertainment. Upon closing the combined entity is expected to be listed on the New York Stock Exchange American under the ticker symbol (AENT). Bruce Ogilvie and Jeff Walker will continue to lead the company as chairman and CEO, respectively. The business combination implies a proforma equity value of the combined company of approximately $480M. Upon completion of the transaction, and assuming no redemptions by public shareholders of Adara, the current owners of Alliance Entertainment will hold approximately 78% of the combined company and current Adara shareholders will hold approximately 22% of the combined company. Alliance Entertainment will receive proceeds of $115M of cash held in trust, less any deferred underwriting commissions, transaction expenses and redemptions by public shareholders of Adara exercising such rights. The transaction, which has been unanimously approved by Alliance Entertainment's and Adara's boards of directors, is expected to close in the fourth quarter of 2022 and is subject to approval by Adara's stockholders and other customary closing conditions, including any applicable regulatory approvals.

08:39 EDT Vinco Ventures announces new distribution date for Cryptyde spin-off - Vinco Ventures announced that the Company's Board of Directors has set June 29, 2022 as the distribution date for the dividend of shares of its common stock of Cryptyde to be distributed, subject to certain conditions, to Vinco stockholders in order to effect the previously disclosed separation of Vinco and Cryptyde into two independent, publicly traded companies. On the Distribution Date, Vinco stockholders entitled to receive the Distribution will receive one share of Cryptyde common stock for every ten shares of Vinco common stock held. After the close of business on May 18, 2022 and continuing up to and including the Distribution Date, there have been two markets in Vinco common stock: a "regular-way" market and an "ex-distribution" market. Shares of Vinco common stock that trade on the "regular-way" market trade with an entitlement to receive shares of Cryptyde common stock in connection with the Distribution. Shares of Vinco common stock that trade on the "ex-distribution" market trade without an entitlement to receive shares of Cryptyde common stock in the Distribution. Therefore, if you sell, or have sold, shares of Vinco common stock on the "regular-way" market after the close of business on the Record Date and up to and including through the Distribution Date, you will be selling, or have sold, your right to receive shares of Cryptyde common stock in connection with the Distribution. If you owned shares of Vinco common stock as of the close of business on the Record Date and sell, or have sold, those shares on the "ex-distribution" market, up to and including through the Distribution Date, you will still receive the shares of Cryptyde common stock that you would be entitled to receive in respect of your ownership, as of the Record Date, of the shares of Vinco common stock that you sell or sold. As of the close of business on the Record Date and continuing up to and including the Distribution Date, there has been a "when-issued" market in Cryptyde common stock. "When-issued" trading refers to a sale or purchase made conditionally because the security has been authorized but not yet issued. The "when-issued" trading market is a market for shares of Cryptyde common stock that will be distributed to Vinco stockholders on the Distribution Date. If you owned shares of Vinco common stock as of the close of business on the Record Date, you would be entitled to receive shares of Cryptyde common stock in connection with the Distribution. You may trade this entitlement to receive shares of Cryptyde common stock, without trading the shares of Vinco common stock you own, in the "when-issued" market. On the first trading day following the Distribution Date, we expect "when-issued" trading with respect to Cryptyde common stock will end and "regular-way" trading in Cryptyde common stock will begin. No fractional shares of Cryptyde common stock will be issued in the Distribution. Instead, fractional shares will be aggregated into whole shares and sold in the open market at prevailing prices and the cash proceeds of such sales will be distributed pro rata to each Vinco stockholder that would otherwise have been entitled to receive a fractional share. No action is required by Vinco stockholders in order to receive the shares of Cryptyde common stock in the dividend distribution. Cryptyde common stock currently trades on the Nasdaq Capital Market under the stock ticker symbol "TYDEV," and after the separation, Cryptyde common stock will trade on the Nasdaq Capital Market under the stock ticker symbol "TYDE" and Vinco will continue to trade on the Nasdaq Capital Market under the stock ticker symbol "BBIG."

08:36 EDT Smart for Life ramps up manufacturing of Milk Dust lactation products - Smart for Life announced that its Doctors Scientific Organica division has accelerated production of Milk Dust, an assortment of proprietary nutritional products and lactation protein powder created for breastfeeding mothers to increase milk supply, nourish the postpartum body and help combat sugar cravings.

08:36 EDT eMagin announced several OLED Microdisplays selected by EO System - eMagin Corporation announced that several of its OLED Microdisplays have been selected by EO System Company for its thermal weapon sights in sniper and motor units and other surveillance systems. With over $1M in current backlog, eMagin has been supplying to EO System Company, in mass production quantities for several years. eMagin's OLED displays were selected due to their high brightness, low power, and high resolution, while operating under a wide range of temperatures desired in defense applications. "We have had a long and successful relationship with EO System Company, and are glad to supply a variety of different OLED microdisplays, most in mass production quantities," said Andrew Sculley, CEO of eMagin Corporation. "EO System Company designs advanced electro-optic systems, and we are able to meet their product requirements from our suite of high-performance OLED microdisplays."

08:35 EDT McKesson to acquire Genospace - Separately, McKesson will acquire Genospace, SCRI's personalized medicine platform. Genospace is an innovator in precision medicine and clinical trial matching. By becoming a part of McKesson, Genospace will power the oncology data and analytics capabilities for the joint venture as well as enhance the ability of its provider partners to more efficiently identify the most appropriate therapies or clinical trials for their patients. Research is essential to advancing cancer care from diagnosis through survivorship, and as such, the joint venture will enhance both companies' cancer care offerings. McKesson's The US Oncology Network and HCA Healthcare's cancer network, Sarah Cannon Cancer Institute, are not part of the transaction and will continue to operate independently of the joint venture. Financial terms of the agreement were not disclosed. The transaction is subject to necessary regulatory approvals and other customary closing conditions.

08:34 EDT AstraZeneca reports detailed results from FoCus Phase 3 trial in Wilson disease - Detailed results from the positive FoCus Phase 3 trial in Wilson disease showed that ALXN1840, an investigational once-daily, oral medicine, met its primary endpoint demonstrating three-times greater copper mobilisation from tissues compared to the standard of care arm, including in patients who had been treated previously for an average of 10 years, AstraZeneca announced. In the trial, people taking ALXN1840 experienced rapid copper mobilisation, with a response at four weeks and sustained through 48 weeks. Results from the trial will be presented on 23 June at the 2022 International Liver Congress, or ILC, in London. Marc Dunoyer, CEO of Alexion, said: "Many people with Wilson disease continue to experience symptoms even after years of intervention with current therapies, illuminating an urgent need to re-evaluate the standard of care. Applying our 30 years of experience in rare disease clinical development, Alexion has conducted rigorous scientific research to bring fresh thinking to Wilson disease around the importance of copper mobilisation from the tissues. These data further our efforts to potentially introduce a novel treatment for patients who have gone decades without meaningful innovation."

08:34 EDT Fathom Digital to join the broad-market Russell 3000 and 2000 Indices June 27 - Fathom Digital Manufacturing announced it is set to join the broad-market Russell 3000 Index and the small-cap Russell 2000 Index at the conclusion of the Russell indexes annual reconstitution, effective after the market opens on June 27, according to a preliminary list of additions posted by FTSE Russell.

08:33 EDT InterDigital appoints Rajesh Pankaj as CTO - InterDigital (IDCC) announced that it has appointed industry veteran, Dr. Rajesh Pankaj as its new Chief Technology Officer, CTO, effective July 5, 2022. Concurrently, Dr. Henry Tirri will move into the role of Senior Advisor to facilitate an orderly transition. Dr. Pankaj joins InterDigital from Qualcomm (QCOM) where he most recently served as the Senior Vice President, Engineering and Head of Corporate R&D, managing a global team of engineers focused on Artificial Intelligence, Edge Computing and new technologies.

08:32 EDT The Very Good Food Company announces agreement with Meijer - The Very Good Food Company is pleased to announce increased U.S. retail expansion via a new agreement with superstore chain Meijer. With 262 supercenters and grocery stores throughout Michigan, Illinois, Indiana, Ohio, and Wisconsin, Meijer's robust Midwest presence represents significant progress towards Very Good's objective to extend its brand and offer products in every major city across the United States. Very Good's Original Ribz and Very Good Steak are included in the agreement with Meijer and will initially be offered at 180 locations.

08:31 EDT Hydrofarm announces departure of President Fitch - Hydrofarm Holdings Group announced that Terence Fitch will step down as President, effective June 24, 2022, to pursue other opportunities.

08:22 EDT Biotricity to join Russell Microcap Index - Biotricity announced that the Company is expected to join the Russell Microcap Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the US market opens on June 27, 2022.

08:21 EDT Mace Security enters partnership with Mid-States Distributing Company - Mace Security International is announcing a new partnership with Mid-States Distributing Company. Mid-States will offer the entire Mace product line to its 36 members that employ over 30,000 associates, with approximately 700 store locations in 33 states and five Canadian provinces. Mace will be participating in the upcoming Mid-States trade show to be held in Phoenix, AZ August 19-20. The Company began communicating the new program to Mid-States' members beginning June 15, 2022 and expects the roll out to be completed within two weeks.

08:19 EDT CN to invest C$15M in Nova Scotia in 2022 - CN announced plans to invest approximately C$15 million in Nova Scotia in 2022. These investments will power sustainable growth and ensure the continued safe movement of goods in Nova Scotia and everywhere on CN's transcontinental network.

08:17 EDT BlueLinx appoints Hall, Burke as RVPs - BlueLinx Holdings (BXC) announced the appointments of Bryan Hall and Joan Burke as Regional Vice Presidents, RVP, of the South and North regions, respectively, with each reporting to Dwight Gibson, President and Chief Executive Officer. Bryan joined BlueLinx on June 13th, with more than 20 years of senior leadership experience in warehousing and distribution, including developing high-performing teams. In his most recent role, Bryan served as the Senior Vice President of Operations at S.P. Richards. Joan begins her role with BlueLinx effective June 27th, 2022. She has more than 30 years of experience across multiple industries. Most recently, Joan worked at Essentra (FLRAF).

08:15 EDT ReWalk Robotics announces 100th placement of an exoskeleton in Germany - ReWalk Robotics announces the 100th placement of an exoskeleton in Germany. The first official reimbursement for a ReWalk exoskeleton supply was by the German statutory accident insurance in June 2015. ReWalk Robotics has entered into framework agreements with several German health insurance companies to provide ReWalk exoskeletons. "These contracts enable all eligible paraplegics to be supplied with an exoskeleton for personal use to stand, walk, and climb stairs during everyday activities at home and in their community" the company said. "For us, the 100th placement of a ReWalk exoskeleton in Germany is an important milestone on the way to improving the quality of life of paraplegic people," says Larry Jasinski, CEO of ReWalk Robotics. "We wish Lukas all the best in his next steps."

08:15 EDT Visteon releases 2022 Corporate Sustainability Report - Visteon Corporation introduced its 2022 Corporate Sustainability Report, which highlights the company's commitment to drive business results in a socially responsible manner and uplift the communities in which it operates. Visteon is a global technology leader serving the mobility industry, dedicated to creating a more connected, clean and safe driving experience. The report covers priorities, product innovations and people initiatives based on 2021 metrics and actions. In 2021, Visteon committed to set longer term greenhouse gas emission reduction targets aligned with the Science Based Targets initiative and reduce total energy and water consumption, solid waste and CO2 emissions from 2019 levels. The company's roadmap to reduce its GHG emissions includes the following actions and initiatives: Accelerate the installation of renewable energy on-site; Collaborate with customers in reducing the carbon footprint of our products; Procurement of renewable energy power purchase agreements; Work closely with Visteon partners to reduce emissions across the supply chain; Communicate progress on energy and emissions reductions to employees, customers, investors and other stakeholders.

08:13 EDT Timber announces first patients enrolled in Phase 3 ASCEND trial of TMB-001 - Timber Pharmaceuticals announced that the first four patients have been enrolled in the pivotal Phase 3 ASCEND clinical trial. ASCEND will evaluate the efficacy, pharmacokinetics and safety of TMB-001 0.05%, a topical isotretinoin formulated using the Company's patented IPEG delivery system, for the treatment of moderate to severe forms of congenital ichthyosis. The U.S. Food & Drug Administration, FDA, awarded a $1.5M grant through its Orphan Products Clinical Trials Grant program to support completed Phase 2a and Phase 2b clinical trials that evaluated TMB-001. The FDA also granted Breakthrough Therapy and Fast Track designations to TMB-001. The first patients were enrolled by Kenneth Dawes, M.D., and his research team at the Dawes Fretzin Dermatology Group in Indianapolis, Indiana. "We are pleased to launch the pivotal ASCEND study and enroll the first patients, which brings us one step closer to delivering an important new treatment option for people who are burdened by the life-long endeavor of managing CI," said John Koconis, Chairman and Chief Executive Officer of Timber. "We believe that TMB-001 has the potential to deliver significant efficacy and relief to patients while minimizing systemic absorption, thereby lowering the rates of side effects seen with the oral compounds."

08:12 EDT ProKidney publishes data from patient study of REACT - ProKidney published data from a patient study confirming the mechanistic action of its lead candidate REACT with cell marker analysis. "Renal Autologous Cell Therapy to Stabilize Function in Diabetes-Related Chronic Kidney Disease: Corroboration of Mechanistic Action with Cell Marker Analysis" by Joseph Stavas et. al. The paper, published in Kidney International Reports, describes observed improvements in renal function and a wide array of clinical parameters in patients with moderate to advanced diabetic CKD treated with REACT. ProKidney's decade-long research, performed in multiple diseased animal models that were treated with the active biological ingredient found in REACT, demonstrated repair of diseased kidneys and the improvement of kidney function. Extensive structural, functional, and biochemical analyses, including biopsies and dissection of the treated animal organs, highlighted that REACT has the potential to promote the development of new functional kidney structures, including glomeruli and tubules, as well as reduce fibrosis and inflammation. In addition, proteomics, genomic, and metabolomic analyses performed on the animal tissues support the mechanism of repair, new kidney tissue formation, and improvement in renal function promoted by the active biological ingredients in REACT. While similar extensive tissue analyses cannot be performed on the kidneys of subjects in clinical trials, analyses of blood and urine are consistent with the findings in the animal studies. REACT is an autologous cell therapy produced from a patient's own kidney cells that is comprised of a proprietary mixture of progenitor cells that have been selected and cultured so they can be placed back into the patient's kidney to restore the natural healing processes. REACT does not require immunosuppression, which is required for allogeneic kidney or cellular transplants. ProKidney's treatment involves a minimally invasive procedure, starting with a standard kidney biopsy, followed by in vitro amplification of selected renal cells, the active biological ingredient in REACT, that are able to harness the body's intrinsic ability to repair and restore damaged kidney tissue. The injection procedure of REACT is done on an outpatient basis with placement in the cortex of the patient's kidney. This procedure has been shown to be well-tolerated when compared to kidney biopsy, a standard diagnostic procedure. ProKidney's RMCL-002 multi-center, randomized Phase 2 trial enrolled 81 stage 3/4 CKD diabetic patients who received two injections in the same kidney six months apart, is ongoing and is evaluating safety, efficacy, and durability of REACT. A paper describing the 81 subject study was published in March 2022 in the American Journal of Nephrology. Of the 81 subjects in RMCL-002, 22 subjects have consented to have further phenotypic and proteomic, genomic, and metabolomic analyses of the cells comprising their personalized REACT product. All 22 subjects had moderate-to-advanced type 2 diabetic CKD. Annualized estimated glomerular filtration rate slopes pre- and post-REACT injection were compared. Fluorescent Activated Cell Sorting analysis for renal progenitor lineages in REACT and vascular endothelial growth factor A analysis were performed. Annualized eGFR slope was -4.63 ml/min per 1/73 m pre-injection and this showed a statistically meaningful improvement post-injection. Around 30% of patients achieved stabilization of kidney function and seven had an eGFR slope of greater than0 ml/min per 1.73 m post-injection. elected renal cells were found to have cell markers from ureteric bud, mesenchymal cap, and podocyte sources and there was production of VEGF, a growth factor associated with maintaining normal nephron function and repair. Improvements were observed in a wide range of clinical parameters pre- and post-injection, including serum creatinine, phosphorus, calcium, and hemoglobin. No SAEs were associated with the biopsies and REACT injections. Other unrelated serious adverse events in this study were common in this population due to the comorbidities of advanced diabetic CKD and metabolic syndrome but were similar in number and characteristics to other historical CKD trials. The conclusions in the Kidney International Report suggested that the selected renal cells in REACT may be able to stabilize and improve kidney function, potentially halting or reversing type-2 diabetic CKD progression or may initiate neo kidney like tissue development to stabilize and improve kidney function and halt type 2 D-CKD progression.

08:10 EDT Hanesbrands announces new primary apparel partnership with USC - HanesBrands announced a new primary apparel partnership with the University of Southern California, or USC. The 10-year agreement gives HBI exclusive rights in the mass and mid-tier retail channels to develop consumer-driven collections of fan apparel that will expand the University's retail footprint. The agreement is in addition to USC's existing relationship with Nike, which is the official outfitter of the 21 varsity Trojan sports and provider of fan merchandise. HBI will design, manufacture and distribute a collection of men's, women's, unisex, youth, infant and toddler fan apparel.

08:10 EDT Farmmi regains compliance with NASDAQ minimum bid price requirement - Farmmi received notification from Nasdaq confirming the company has cured the bid price deficiency, and that the company is in compliance with all applicable listing standards. As a result, the scheduled hearing before the Nasdaq Hearings Panel has been cancelled. The company's stock will continue to be listed and traded on Nasdaq.

08:09 EDT Reliance Global launches homeowner's insurance of 5MinuteInsure.com - Reliance Global Group announces the launch of homeowner's insurance on 5MinuteInsure.com. The Company has also introduced bundled home and auto policies for additional savings.

08:08 EDT electroCore announces listing transfer to Nasdaq Capital Market - electroCore announced that it has received approval from the Nasdaq Stock Market to transfer the listing of its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market. The Company's common stock will continue to be traded under the symbol "ECOR" and trading of its common stock will be unaffected by this transfer. This transfer will be effective as of the opening of business on June 23, 2022. As previously disclosed, on December 20, 2021, the Company received a letter from Nasdaq notifying the Company of its noncompliance with Nasdaq Listing Rule 5450(a)(1) by failing to maintain a minimum closing bid price for its common stock on the Nasdaq Global Select Market of at least $1.00 per share for 30 consecutive business days. The Company was given a period of 180 calendar days, or until June 20, 2022, to regain compliance with the minimum closing bid price requirement. In response to not achieving the minimum closing bid price, the Company submitted an application to transfer its listing from the Nasdaq Global Select Market to the Nasdaq Capital Market. In connection with the transfer, Nasdaq granted the Company a second period of 180 calendar days, or until December 19, 2022, to regain compliance with the minimum closing bid price requirement for continued listing by achieving a closing bid price on Nasdaq of at least $1.00 per share for 10 consecutive business days. Nasdaq granted the additional 180-day compliance period as the Company continues to meet the listing requirements of the Nasdaq Capital Market with the exception of the minimum closing bid price requirement. The Company intends to continue to actively monitor its compliance with the minimum closing bid price requirement and, as appropriate, will consider available options to resolve any deficiencies and regain compliance.

08:07 EDT Siga Technologies announces $13M of procurement orders for oral TPOXX - SIGA Technologies announced approximately $13M of procurement orders for oral TPOXX, including $11M for initial procurement from two new international jurisdictions and an approximate $2M order from a country in the Asia Pacific region that has an established contract for oral TPOXX. "Procurement orders from new international jurisdictions have occurred as SIGA has received a large and ongoing number of inquiries about accessing oral TPOXX, highlighting the importance of health security preparedness," said Phil Gomez, CEO of SIGA. "We expect a portion of the courses of oral TPOXX delivered under these orders will be used for the treatment of active monkeypox cases and represent a first step in the response to this outbreak by the global public health community. By increasing both the scale and scope of TPOXX stockpiling, countries can be better prepared for the outbreak risks of smallpox, monkeypox, and other viruses in the orthopoxvirus family of viruses and make sure that patients are able to access a proven safe and effective treatment." The orders from the new international jurisdictions represent the first procurements of oral TPOXX directly in response to the evolving global monkeypox outbreak. One of the new jurisdictions is located in Europe and the other is located in the Asia Pacific region. SIGA currently expects to deliver approximately $4M of oral TPOXX under the two new contracts within the next 45 days. The remaining approximately $7M of oral TPOXX is expected to be delivered in 2023. With respect to the order from an existing customer, SIGA recently fulfilled the order by delivering $2M of oral TPOXX. In combination with a delivery of a previously disclosed order of $2.8 million, SIGA has delivered in total approximately $5M of oral TPOXX to this country during this quarter. Meridian Medical Technologies is the counterparty to the international contracts and SIGA will be responsible for the manufacture and delivery of product.

08:06 EDT H2O Innovation announces renewal of operation, maintenance contract - H2O Innovation announced that it has recently renewed the operation, management and maintenance contract with Monroe County, Georgia, USA, for an additional period of five years. This contract, valued at $3.3 M, brings the Corporation's O&M backlog to $131.5 M. This renewal includes annual consumer price index increases and the addition of one employee.

08:05 EDT Healthcare Triangle announces availability of Digital Front Door app - Healthcare Triangle announces the availability of the Digital Front Door mobile app solution. The company said, "The evolving healthcare consumer engagement landscape has pushed healthcare technology leaders to realize the need for an effective Digital Front Door mobile app that puts patients at the heart of the digital healthcare experience. While many healthcare providers are unsure how to get started, there has never been a more urgent need for hospitals to elevate patient engagement and deliver a differentiating experience. Keeping up with accelerated digital transformation can be daunting, but Healthcare Triangle alleviates the pressure."

08:05 EDT Amyris begins fermentation at new plant in Barra Bonita, Brazil - Amyris announced that it has successfully started fermentation at its new precision fermentation plant in Barra Bonita, Brazil. The greenfield site at Barra Bonita establishes Amyris as the leading manufacturer of highly engineered organisms at industrial scale. The first of its kind precision fermentation plant is a strategic investment made to meet rapidly growing demand for clean, sustainable, chemistry-based products for the beauty, personal care, health and wellness markets. The plant consists of five precision fermentation "mini-factories" capable of concurrently producing all 13 of Amyris' molecules currently in the market as well as future bio-fermented products. The plant's capacity is fully committed through the end of 2023 with the production of natural vanillin, sugarcane-based Reb M, squalane, squalene, hemisqualene and patchouli along with other molecules. The plant will allow Amyris to more efficiently meet demand from its ingredient customers after several years of operating under third-party capacity supply constraints.

08:03 EDT Splash Beverage enters agreement to acquire 80% of Pulpoloco Sangria - Splash Beverage Group announced that it has signed an agreement to acquire 80% of Pulpoloco Sangria in a transaction that will give Splash control over the manufacturing and distribution of Pulpoloco across the US while adding international markets, capturing the additional margin and revenue. Splash acquired the distribution rights to Pulpoloco in 2020 and is currently the exclusive importer of Pulpoloco for the United States. Robert Nistico, Splash Beverage Group's Chairman and CEO, commented, "In addition to bringing Pulpoloco entirely under the Splash roof, we will benefit from the additional layer of margin AND increase our global footprint and revenue. Pulpoloco was the only brand in our portfolio where we were not directly responsible for the manufacturing. Owning the manufacturing process entirely, which includes the exclusive rights of the innovative eco-friendly packaging, not only expands those rights, but will provide us with the opportunity to ship in greater bulk and to markets with faster growth potential. We believe this will help us add scale and drive additional revenue growth while potentially improving margins."

08:03 EDT Jiuzi Holdings signs purchase order for up to 1,000 electric vehicles - Jiuzi Holdings' operating entity, HangzhouZhitongche Technology, has entered into a purchase agreement with an authorized sales agent of WM Motor, a Shanghai-based automotive company specialized in the manufacturing of battery-driven electric vehicles - BEVs -. This agreement signifies the start of the company's new campaign to expand its contact with automaker suppliers. Pursuant to the Agreement signed in May, Zhitongche will purchase up to 1,000 Weltmeister electric vehicles from the sales agent, and the delivery time is expected to be in the second half of 2022. The company expects to order about 5,000 to 8,000 EV cars from the sales agent in the next three years and become the most significant domestic distributor of Weltmeister EV cars.

08:02 EDT Cullinan, Taiho complete agreement for collaboration to jointly develop CLN-081 - Cullinan Oncology announced the completion of its agreement with Taiho Pharmaceutical signed in May 2022. Per the terms of the agreement, the companies will collaborate on the U.S. development of CLN-081/TAS6417, a next generation, irreversible EGFR inhibitor for the treatment of a genetically defined subset of patients with non-small cell lung cancer. Taiho has also completed its acquisition of Cullinan Oncology's subsidiary, Cullinan Pearl, which has worldwide rights outside of Japan to CLN-081/TAS6417. Taiho has provided an upfront payment to Cullinan Oncology of $275 million with the potential for an additional $130 million tied to EGFR exon20 NSCLC regulatory milestones. In addition, the two companies have agreed to co-develop and co-commercialize CLN-081/TAS6417. Cullinan Oncology retains the option to co-commercialize CLN-081/TAS6417 in the United States together with Taiho through its U.S. subsidiary, Taiho Oncology, Inc. Taiho and Cullinan Oncology will equally contribute to the future clinical development of CLN-081/TAS6417 in the U.S., with each receiving 50% of the profits from potential U.S. sales.

08:00 EDT F star Therapeutics trading resumes

07:46 EDT Innovation Pharmaceuticals reports brilacidin inhibits SARS-CoV-2 variants - Innovation Pharmaceuticals reported that Brilacidin, the Company's defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity, inhibited the Omicron and Delta variants of SARS-CoV-2 based on in vitro testing conducted in collaboration with National Institutes of Health National Institute of Allergy and Infectious Diseases scientists. Researchers at Rutgers University have also shown Brilacidin inhibited in vitro the Gamma and Alpha variants of SARS-CoV-2. Brilacidin has now been tested in vitro in seven SARS-CoV-2 strains and three human coronavirus strains in addition to MERS-CoV and SARS-CoV-1. Brilacidin has consistently inhibited all coronaviruses tested, independent of cell type, at generally attainable systemic concentrations. Identifying COVID-19 countermeasures with novel mechanisms of action is vital. SARS-CoV-2 continues to evolve at an accelerated pace, raising questions as to what the dominant variant may be this fall and winter, when infections often spike -- and if today's COVID-19 vaccines and therapeutics can maintain their effectiveness. Emerging SARS-CoV-2 variants, and increasingly their sub-variants, contain immunity-evading mutations. These mutations alter key parts of the SARS-CoV-2 spike protein that attach to human cells, making the virus more transmissible and potentially more virulent. Unlike other antivirals, such as monoclonal antibodies, and most vaccines, Brilacidin has been shown not to target the Spike S1 and Spike RBD regions of SARS-CoV-2, acting instead through dual-acting neutralizing and blocking antiviral properties, able to target virus and host. These antiviral traits support Brilacidin's ability to maintain its anti-coronavirus activity and suggest Brilacidin would be less subject to resistance. Related, results from new NIH/NIAID in vitro testing of Brilacidin in over 20 acutely infectious viruses, and from the Brilacidin Phase 2 COVID-19 clinical trial, are being prepared for publication. Findings from the Rutgers' Brilacidin research can be accessed at the link below1 and build on earlier published Brilacidin research conducted by scientists at George Mason University and at University of Arizona and University of California-San Francisco. In 2021, the Company completed a Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 patients. While the trial did not meet its primary endpoint in reducing time to sustained recovery through day 29, certain patient subgroups did show treatment benefits of Brilacidin for that primary endpoint. For example, patients treated early from onset of symptoms achieved sustained recovery more quickly. To date, only a modicum of success has been demonstrated by any company conducting clinical trials in moderate-to-severe hospitalized cases of COVID-19. A possible reason for this may be owing to frequent changes in the standard of care with patients receiving a cocktail of fluctuating concomitant medications, which complicates the interpretation of the clinical trial data and that of the new drug candidate being evaluated. Clinical observations of COVID-19 patients treated with Brilacidin further lead us to believe that higher and more frequent dosing of Brilacidin may be more appropriate to tackle this complex disease in the hospital setting. Taken together, the results from NIH/NIAID testing of Brilacidin are supportive of previously completed research and give the Company confidence in the compound's antiviral potential. The Company remains active in pursuing additional government-based funding opportunities, as well as licensing partnerships, to advance Brilacidin in the highly attractive area of developing novel broad-spectrum medicines for treating viral diseases.

07:39 EDT Evaxion Biotech expands EVX-03 DNA Vaccine Program into NSCLC - Evaxion Biotech announced that it has selected EVX-03 as the product candidate within its DNA technology platform to target a new indication with planned regulatory filing in H2 2022. The company said, "We currently have two product candidates in our DNA technology platform, EVX-02, and EVX-03. Based on very encouraging results from our pre-clinical studies of EVX-03, we have decided to use this candidate in an upcoming clinical trial in a new indication." EVX-03 is optimized with an APC-targeting unit, which has shown promising pre-clinical data and significant tumor reduction at very low doses as well as a clear dose-response relationship in all our preclinical models. Evaxion has decided to continue the development of EVX-03 in patients with advanced disease and plans to target non-small cell lung cancer with EVX-03.

07:36 EDT Diffusion Pharmaceuticals announces effect in Altitude Trial - Diffusion Pharmaceuticals announced positive effects from its second Oxygenation Trial, the Altitude Trial. "This was a specialized study designed to evaluate TSC's novel oxygen-enhancing mechanism when administered under hypoxic and physically stressful conditions. Subjects were exposed to simulated high altitude with resultant hypoxia and then rode a bike to exhaustion under a stepped protocol. We believe the positive effects in this trial on serum markers of pH and lactate, as well as improvement in oxygen saturation recovery after exercise, further supports the thesis that TSC enhances oxygen diffusion to tissue under hypoxic conditions," said Chris Galloway, MD, Chief Medical Officer of Diffusion. "When combined with the positive effects observed in the TCOM Trial and the clinical effects observed in our prior clinical trials, we believe these data support our plans for further development of TSC to treat conditions complicated by hypoxia," he added. Study Results: In the Altitude Trial, following exercise under hypoxic conditions, an increase in pH and a decrease in lactate were observed in the study subjects treated with the highest dose of TSC, both at the end of the exercise period and at 10 minutes post-exercise. These data suggest the 2.5 mg/kg dose of TSC decreased blood acidity and enhanced metabolic recovery at 10 minutes after completion of exercise under the stressful conditions of simulated high altitude and exercise. Specific results include the following: positive effects on lactate and pH were observed with the TSC 2.5 mg/kg dose at the end of the exercise period versus the baseline measurement. A "carry-over" effect was observed in subjects who received TSC in the first treatment of the day versus those who received placebo first and TSC for the second ascent. The 2.5 mg/kg dose appeared to have a positive effect on post-exercise recovery based on comparison of the measurements for pH, lactate, oxygen saturation and other markers at 10 minutes post-exercise versus last exercise measurements. There were no observed changes among subject's intra-day maximal oxygen consumption tests or in subject's partial pressure of arterial blood oxygen. TSC was safe and well-tolerated at all doses tested in the study with no serious adverse events reported.

07:35 EDT Soligenix vaccine shows 100% protection in primates vs. Ebola,Marburg viruses - Soligenix announced 100% protection of non-human primates - NHPs - against lethal Marburg marburgvirus challenge using a bivalent, thermostabilized vaccine formulated in a single vial, reconstituted only with sterile water immediately prior to use. This follows the previous successful demonstration of 100% protection against lethal Sudan ebolavirus challenge. It demonstrates the applicability of the heat stable vaccine platform, and its potential role in the US Administration's initiative for pandemic preparedness. This same heat stable vaccine platform has also been applied to the development of a COVID-19 vaccine, CiVax. The antigens and adjuvants used in this study have been previously shown to protect NHPs from subsequent infection, and represent the only recombinant subunit vaccines to date that have demonstrated full protection against challenge with Zaire ebolavirus, SUDV and MARV in NHPs. The thermostabilized filovirus vaccine program is continuing to advance with the support of a National Institute of Health grant and a Small Business Innovation Research grant awarded to Soligenix.

07:33 EDT Cognition Therapeutics doses first patient in study of CT1812 - Cognition Therapeutics announced that the first patient has been dosed in its double-blind, placebo-controlled, randomized Phase 2 SHIMMER clinical trial of CT1812 in patients with dementia with Lewy bodies, DLB. CT1812 is an experimental, orally delivered small molecule therapeutic intended to address the underlying biology of DLB. DLB is a multi-faceted disorder characterized by the accumulation of alpha-synuclein fibrils, the major constituent of the Lewy bodies that occur inside brain neurons, which exert deleterious effects across brain structures. In addition, many patients with DLB also have a buildup of Abeta oligomers. Cognition anticipates enrolling 120 adults between 50 and 80 years of age with a DLB diagnosis, who will be randomized to receive placebo or one of two daily doses of CT1812 for six months. In addition to safety, this study will compare changes in cognitive performance, physical activity, and pharmacokinetic and pharmacodynamic biomarkers to baseline measurements. Furthermore, cerebrospinal fluid will be collected and analyzed for alpha-synuclein content and established patterns of differential protein expression. "DLB is a poorly understood disease with no approved treatments and few active clinical research efforts. We are excited to explore the potential that our -2 receptor modulator, CT1812, may have therapeutic benefit for patients with this intractable disease," added Anthony Caggiano, M.D., Ph.D., chief medical officer and head of R&D at Cognition Therapeutics. "Initiation of patient treatment in this interventional study is an important milestone for Cognition Therapeutics and for the DLB community. We are grateful to our collaborators at the Lewy Body Dementia Association and the Miller School of Medicine; as well as the continued support from the National Institute on Aging, who awarded Cognition the largest grant to date to study DLB."

07:33 EDT Hyzon Motors announces joint development agreement with Schlumberger - Hyzon Motors (HYZN) is teaming up with Schlumberger (SLB) to reduce emissions in upstream oil & gas operations with power generated by its heavy duty fuel cell systems. Hyzon, a global supplier of zero-emissions hydrogen-powered and fuel cell electric commercial vehicles, announced a joint development agreement with Schlumberger. Under the JDA, Hyzon will utilize its expertise in engineering and manufacturing high-power fuel cell systems for heavy-duty commercial mobility to co-develop zero-emissions fuel cell power generation solutions initially for North American oil & gas well construction for land drilling rigs, with opportunities for collaboration into other field operations in the broader oil & gas market. Hyzon's technology is intended to be integrated into Schlumberger's portfolio of Intelligent Power Management solutions and powered by Hyzon. Currently in the initial phase of the JDA, the companies expect to demonstrate the first fuel cell power module in oil & gas field operations as early as Q4 of 2022, starting with powering an onshore drilling rig application. Under the JDA, Schlumberger will also provide customer validation opportunities and will lead the anticipated commercialization of the product to existing and new customers. As an initial step, Schlumberger has already executed a Memorandum of Understanding to integrate the fuel cell solution in Ensign Energy Services drilling operations within the next twelve months.

07:23 EDT LVMH, Bambuser sign three-year renewal of master agreement - Bambuser announced it has signed a renewal of the Master Agreement with LVMH Moet Hennessy Louis Vuitton. The Master Agreement includes the One-to-One and the One-to-Many solutions from the Bambuser product suite. LVMH is extending the existing agreement for 3 years, the maximum duration of time the group sign vendor agreements.

07:19 EDT Ondas signs LOI to develop radio platform for European rail market - Ondas Holdings announced that Ondas Networks signed a letter of intent with a partner to develop a new on-board locomotive radio platform for the European rail market. The new platform will support train equipment for on-board communications, which includes compatibility with the existing wayside base station network. The new on-board locomotive radio platform integrates Ondas' Next-Generation software defined radio technology, which is currently being incorporated into products under development this year for the North American and Asian locomotive markets. The new European program is anticipated to be completed in 2023 with deliveries commencing that year.

07:17 EDT Emerita Resources announces assay results for hole LR002 - Emerita Resources announces assay results for hole LR002 which is the first drill hole completed at the Romanera deposit at Emerita's wholly-owned Iberia Belt West Project. As previously reported on June 7, 2022, Hole LR002 intersected 14.3 meters of massive sulphides from 134.2 meters. Three additional drill holes have been completed to date and also appear to have intersected significant sulfide mineralization. According to David Gower, P.Geo, CEO of Emerita, "We had a sense from reviewing certain of the historical data that the deposit could be enriched in precious metals. Interestingly most of the upper part of the deposit as delineated by historical drilling was never assayed for gold. This presents significant upside potential even within the area."

07:14 EDT Duluth Holdings appoints Riley to board of directors - Duluth Holdings announced the appointment of Susan Riley to its Board of Directors effective June 27, 2022. Riley most recently served as Interim President and Chief Executive Officer at PJM Interconnection.

07:12 EDT McEwen Mining provides third progress report for Los Azules project - McEwen Copper, a subsidiary of McEwen Mining, provides its 3rd progress report on the advancement of its large Los Azules copper project located in the San Juan province, Argentina. The objectives of its 59,000-meter drilling program at Los Azules is to: upgrade the Inferred mineral resources to Indicated; conduct metallurgical, hydrological and geotechnical drilling to accelerate our study work; and selectively test high value exploration targets. This program will almost double the historic database of 66,000 m of drilling from 202 holes.

07:11 EDT Akoustis signs new DARPA contract to advance XBAW technology - Akoustis Technologies announced that it has entered into a new multi-year, multi-million dollar contract from the Defense Advanced Research Projects Agency, DARPA, to pursue new materials and device manufacturing methods. As a result of the expected advances, the program could extend the Company's patented and proprietary XBAW technology to 18 GHz, opening up significant new commercial and defense applications to Akoustis. In this DARPA program, XBAW technology utilizes a novel approach to circumvent trade-offs inherent in traditional BAW frequency scaling approaches. Akoustis plans to introduce, at the completion of the program, XBAW filters and resonators that fully exploit the entire kt2 of the underlying piezoelectric material. Jeff Shealy, founder and CEO of Akoustis, stated, "A different frequency scaling approach is required for BAW resonators to operate at higher frequencies above 10GHz, such as X and Ku bands." Shealy continued, "In this DARPA-funded effort, we intend to introduce a new method of BAW overtone operation that can maintain high Q factor while mitigating the decrease in coupling. Combining our existing, patented XBAW technology along with the successful mode overtone operation which we plan to develop under this program, we expect to advance the state-of the-art in BAW RF filter technology at lower frequencies for 5G and Wi-Fi-specifically in terms of power handling, Q factor and frequency operation relative to incumbent BAW technologies in the market today."

07:09 EDT Viridian Therapeutics appoints Melvin as Chief Operating Officer - Viridian Therapeutics (VRDN)announced the appointment of Carrie Melvin as Chief Operating Officer, a newly created position at the company. Melvin has over 20 years of experience at pharmaceutical and biotechnology companies. Melvin served as Senior Vice President of Clinical Development Operations at X4 Pharmaceuticals (XFOR).

07:07 EDT Methode Electronics announces three-year sales target - The company has announced a three-year organic sales compounded annual growth rate target of 6%. The base year for this target is Fiscal 2022. The target excludes any impact from foreign currency, acquisitions, or divestitures.

07:06 EDT Darden announces new $1B share repurchase program - This repurchase program does not have an expiration and replaces the previously existing share repurchase authorization.

07:05 EDT Bloom Energy installs one megawatt of solid oxide fuel cells at Ferrari factory - Bloom Energy set a new pace for Ferrari's drive to achieve carbon neutrality in manufacturing by 2030, announcing a one megawatt installation of Bloom's solid oxide fuel cells at Ferrari's expanding manufacturing facility and headquarters in Maranello, Italy. The partnership with Ferrari, a global leader in the luxury and automotive sectors for 75 years, marks Bloom's entry into the European Union and Italy and is the first step toward potentially larger projects between the two companies. Bloom Energy's highly efficient platform converts fuels such as hydrogen, biogas, or natural gas into clean electricity without combustion. Through Bloom's solid oxide platform, Ferrari is expected to be able to reduce its fuel consumption and carbon emissions at its manufacturing facility while unlocking cost and sustainability benefits. Operating at superior efficiencies, Bloom Energy Servers will initially provide 5 percent of the energy needed at Ferrari's Maranello headquarters and manufacturing center. The Bloom Energy Servers are expected to cut gas requirements by around 20% from the combined heat and power system now in use at Ferrari, while also reducing emissions. This will enable Ferrari to bolster energy conservation amid record-high energy prices, while simultaneously reducing greenhouse gas emissions and improving local air quality, with virtually zero harmful air pollutant emissions such as sulfur oxides, nitrogen oxides, and particulate matter.

07:01 EDT Darden raises quarterly dividend 10% to $1.21 per share - The dividend is payable on August 1 to shareholders of record at the close of business on July 8.

06:54 EDT Accenture raises FY22 negative FX impact view to 4.5% from 3% - Accenture's business outlook for the full 2022 fiscal year now assumes that the foreign-exchange impact on its results in U.S. dollars will be approximately negative 4.5% compared with fiscal 2021; the company previously expected a negative 3% foreign-exchange impact. Accenture continues to expect operating margin for the full fiscal year to be 15.2%, an expansion of 10 basis points from fiscal 2021. The company now expects its annual effective tax rate to be in the range of 23.5% to 24.5%, compared with 23% to 25% previously.

06:51 EDT Denison Mines enters participation, funding agreement with KML - Denison Mines announced that it has entered into a participation and funding agreement with Kineepik Metis Local #9, or KML, which expresses Denison's and KML's mutual commitment to the co-development of an agreement supporting the advancement of the in-situ recovery, or ISR, uranium mining operation proposed at the company's 95% owned Wheeler River Uranium Project. The participation agreement builds on an existing letter agreement between Denison and KML with respect to the support of KML's contributions to, and participation in, the Federal and Provincial Environmental Assessment process for the Wheeler River Project.

06:49 EDT Accenture sees FY22 operating cash flow $8.7B-$9.2B - For fiscal 2022, the company continues to expect operating cash flow to be in the range of $8.7B-$9.2B; continues to expect property and equipment additions to be $700M; and continues to expect free cash flow to be in the range of $8B-$8.5B. The company continues to expect to return at least $6.5B in cash to shareholders through dividends and share repurchases.

06:46 EDT Melco Resorts & Entertainment's gaming subconcession in Macau extended - Melco Resorts & Entertainment's Melco Resorts Macau, a subsidiary of the company, and Wynn Resorts Macau entered into an Amendment Agreement to the Subconcession Contract pursuant to which the gaming subconcession of Melco Resorts Macau, which is due to expire on June 26, was extended to December 31, 2022, which coincides with the extended expiration date of all the other concessions and subconcessions. Melco Resorts Macau will pay the Macau government the equivalent of approximately $5.8M upon signing of the Extension Agreement as premium for such extension. Melco Resorts Macau will also submit a bank guarantee in an amount of not less than approximately $101.4M to the Macau government within three months from the date of signing of the Extension Agreement to guarantee the satisfaction of any labor liabilities upon expiry of the subconcession. The gaming areas, gaming support areas and the gaming equipment of Altira Casino, City of Dreams Casino and Studio City Casino, as agreed with the Macau government, will revert to the Macau SAR, without compensation and free and clear from any charges or encumbrances at the expiration of the subconcession. In addition, certain conditions imposed by the Macau government relating to the previously existing agreement, including in relation to shareholding requirements for certain direct and indirect shareholders of Studio City Entertainment Limited, are no longer applicable.

06:32 EDT Westwater Resources CFO Jeffrey Vigil to retire, Steven Cates to succeed - Westwater Resources (WWR) announced the retirement of Jeffrey Vigil, CFO and Vice President - Finance, effective August 26. Chief Accounting Officer Steven Cates has been elected Westwater's new CFO and Vice President - Finance, also effective August 26. Prior to joining Westwater, Cates served as the Vice President - Controller for Apartment Income REIT (AIRC), a real estate investment trust focused on apartment communities.

06:09 EDT New York City REIT reports 140K square feet of new and renewed leases - New York City REIT has executed one new lease and three lease renewals in its pure-play New York City portfolio. A new, 4,700 square foot lease with a five-year term was signed at 9 Times Square, replacing former Knotel space. In addition, NYC executed three long-term renewals: two fifteen-year leases with entities controlled by City Parking for the company-owned parking garages at 200 Riverside and 400 East 67th Street and one 10-year lease renewal with the Government Services Administration, a 48,000 square foot lease at 123 William Street. The GSA and parking garage leases commence on or before July 1 and the lease at 9 Times Square is expected to commence on August 1. Combined, these leases require tenants to pay over $4.2M in annualized, straight-line rent, $1M of which is net new SLR, and have a weighted-average remaining lease term of almost 12 years.

06:06 EDT Vizio Smart TVs now integrated with Tik Tok TV - Vizio announced that TikTok TV is now available on Vizio Smart TVs. This integration allows Vizio users to discover videos from TikTok directly from the Vizio home screen - no downloads required. In support of this launch, Vizio will highlight TikTok TV content on the Vizio Home Page in a dedicated carousel showcasing popular trending genres so users can more easily discover their next favorite TikTok videos. The TikTok TV app has been specifically created for a TV home-viewing experience.

06:05 EDT Quanergy names Lori Sundberg as Chief Human Resources Officer - Quanergy announced that Lori Sundberg has joined the company in the role of Chief Human Resources Officer. She brings over three decades of human resources experience to Quanergy, having previously worked for Western Digital, Jacobs, American Express, Arizona Public Service and others.

05:31 EDT Novartis says FDA grants accelerated approval for Tafinlar + Mekinist - Novartis announced the U.S. Food and Drug Administration granted accelerated approval for Tafinlar + Mekinist for the treatment of adult and pediatric patients 6 years of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. In accordance with the Accelerated Approval Program, continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). "Tafinlar + Mekinist is the first and only BRAF/MEK inhibitor to be approved with a tumor-agnostic indication for solid tumors carrying the BRAF V600E mutation, which drives tumor growth in more than 20 different tumor types, and it is the only BRAF/MEK inhibitor approved for use in pediatric patients," the company stated.

05:15 EDT Boeing signs on for Aireon ADS-B data services - Aireon will deliver its flight data stream to Boeing. Boeing will use the stream to expand its advanced data analytics capabilities in its effort to further strengthen commercial air travel safety. Aireon will provide historical aircraft data and near real-time aircraft event data via its AireonINSIGHTS product for select Boeing airplane programs. As part of its implementation of an enterprise Safety Management System, or SMS, Boeing will integrate the ADS-B data into its safety analytics tools. Recognized worldwide as an industry best practice, SMS is an integrating framework for managing safety risks. Through the use of data science and data analytics, the information will deliver insights to proactively identify hazards and monitor emerging safety trends.